In addition to hormone-related tumors, several factors, including inactivating mutations in tumor suppressors (TP53) and activation of oncogenes (EGFR or MYC) in this study, provided clinical insights into m7G in lung cancer. The gene discussed is EGFR; the disease is lung carcinoma.